Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

← catalyst calendar

NCT02665065

Sponsored by Actinium Pharmaceuticals (industry) · ATNM — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
153actual
Sites
24
Countries
Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
StartJun 2016not statedWhen the study began enrolling
Primary completionJun 2022actualThe date the last participant is measured for the primary outcome — the readout window
Study completionDec 2026estimatedThe whole study's end, after follow-up
First posted2016-01-27estimatedWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2023-07-19actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Acute Myeloid Leukemia
  • Leukemia, Acute Myeloid
  • Myeloid Leukemia, Acute
  • Leukemia, Myeloid, Acute
  • Acute Myelogenous Leukemia
  • Leukemia, Acute Myelogenous
  • Myelogenous Leukemia, Acute
  • AML
  • Bone Marrow Transplant

Interventions

  • Drug: Iomab-B
  • Drug: Conventional Care
  • Procedure: HCT

Primary outcome

what the primary-completion date above is the date OF
Durable Complete Remission (dCR)
measured 6 months from time of initial CR or CRp

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ATNM's whole pipeline · Catalyst calendar · Every registered study · What changed